Mylan Institutional, Inc. is recalling 1,415 cartons of Levothyroxine Sodium Tablets (levothyroxine sodium) in 150 mcg and 125 mcg strengths. The recall was initiated because testing showed the tablets were super-potent, meaning they contain more of the active thyroid medication than specified. If you have health concerns, contact your healthcare provider or pharmacist. Return any unused product to the place of purchase for a refund, throw it away, or contact Mylan Institutional, Inc. for further instructions.
Taking medication with higher potency than prescribed can lead to hyperthyroidism, which may cause an irregular heartbeat, increased blood pressure, and other hormonal complications. No incidents or injuries have been reported to date regarding this specific recall.
You have 2 options:
Recall #: D-0290-2025; Quantity: 347 Cartons
Recall #: D-0291-2025; Quantity: 1,068 cartons
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.